Xbrane Biopharma
A biotechnology company specializing in the development of biosimilars.
XBRANE | ST
Overview
Corporate Details
- ISIN(s):
- SE0007789409 (+1 more)
- LEI:
- 5493008DKD05APTKQO39
- Country:
- Sweden
- Address:
- RETZIUS VÄG, 8, 171 65 Solna
- Website:
- https://xbrane.com/en/
- Sector:
- Manufacturing
Description
Xbrane Biopharma is a biotechnology company that specializes in the development of biosimilars—follow-on versions of approved biological drugs. The company's mission is to enhance the accessibility of biological treatments for serious diseases by creating more affordable alternatives. Xbrane utilizes a patented platform technology and efficient manufacturing systems, employing both bacterial and mammalian cells, to achieve lower production costs. Its development pipeline includes several biosimilar candidates, with a key product being a ranibizumab biosimilar.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-03 10:15 |
Kallelse till årsstämma i Xbrane Biopharma AB
|
Swedish | 120.8 KB | ||
| 2023-04-03 10:15 |
Notice of annual general meeting in Xbrane Biopharma AB
|
English | 119.8 KB | ||
| 2023-04-03 07:00 |
STADA och Xbrane lanserar ranibizumab för att öka tillgängligheten för patiente…
|
Swedish | 83.6 KB | ||
| 2023-04-03 07:00 |
STADA and Xbrane launch ranibizumab to support patient access in Europe
|
English | 83.6 KB | ||
| 2023-03-31 17:05 | Swedish | 2.2 MB | |||
| 2023-03-31 17:05 | Swedish | 2.2 MB | |||
| 2023-02-17 08:00 | Swedish | 1.1 MB | |||
| 2023-02-17 08:00 | English | 1.1 MB | |||
| 2023-01-17 08:00 |
STADA and Xbrane obtain British approval for Ximluci® (ranibizumab) biosimilar …
|
English | 81.9 KB | ||
| 2023-01-17 08:00 |
STADA och Xbrane erhåller godkännande i Storbritannien för Ximluci® (ranibizuma…
|
Swedish | 82.7 KB | ||
| 2022-12-15 08:00 |
XBRANE PROVIDES AN UPDATE ON RANIBIZUMAB BIOSIMILAR CANDIDATE FDA FILING
|
English | 69.1 KB | ||
| 2022-12-15 08:00 |
XBRANE UPPDATERAR OM ANSÖKAN AVSEENDE MARKNADSGODKÄNNANDE TILL FDA FÖR SIN RANI…
|
Swedish | 70.1 KB | ||
| 2022-11-11 08:55 |
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar refer…
|
English | 83.7 KB | ||
| 2022-11-11 08:55 |
STADA och Xbrane erhåller EU-godkännande för Ximluci® (ranibizumab) biosimilar …
|
Swedish | 78.2 KB | ||
| 2022-10-31 08:00 |
Förändrat antal aktier och röster i Xbrane
|
Swedish | 65.8 KB |
Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xbrane Biopharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-17 | Karl Martin Erik Åmark | Other | Buy | 1,864,223 | 318,782.13 SEK |
| 2025-01-17 | Karl Martin Erik Åmark | Other | Sell | 1,864,223 | 315,053.69 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Sell | 1,519,932 | 260,212.36 SEK |
| 2025-01-16 | Siavash Bashiri | Other | Buy | 1,500,000 | 256,500.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Buy | 4,000 | 129,000.00 SEK |
| 2023-09-12 | Karl Martin Erik Åmark | Other | Sell | 4,000 | 128,200.00 SEK |
| 2023-09-11 | Karl Martin Erik Åmark | Other | Sell | 2,000 | 62,140.00 SEK |
| 2023-09-08 | Siavash Bashiri | Other | Sell | 5,890 | 194,959.00 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | 968.54 SEK |
| 2023-09-08 | Karl Martin Erik Åmark | Other | Other | 4,320 | N/A |
Peer Companies
